Rathbones Group’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,275
| Closed | -$243K | – | 665 |
|
|
2025
Q3 | $243K | Sell |
2,275
-4,596
| -67% | -$480K | ﹤0.01% | 547 |
|
|
2025
Q2 | $650K | Sell |
6,871
-1,347
| -16% | -$99.7K | ﹤0.01% | 402 |
|
|
2025
Q1 | $522K | Sell |
8,218
-2,000
| -20% | -$120K | ﹤0.01% | 403 |
|
|
2024
Q4 | $475K | Sell |
10,218
-1,683
| -14% | -$63.2K | ﹤0.01% | 420 |
|
|
2024
Q3 | $342K | Sell |
11,901
-3,950
| -25% | -$97.2K | ﹤0.01% | 458 |
|
|
2024
Q2 | $229K | Sell |
15,851
-125
| -0.8% | -$1.82K | ﹤0.01% | 532 |
|
|
2024
Q1 | $257K | Hold |
15,976
| – | – | ﹤0.01% | 514 |
|
|
2023
Q4 | $318K | Hold |
15,976
| – | – | ﹤0.01% | 468 |
|
|
2023
Q3 | $260K | Buy |
15,976
+6,392
| +67% | +$123K | ﹤0.01% | 496 |
|
|
2023
Q2 | $203K | Buy |
+9,584
| New | +$204K | ﹤0.01% | 376 |
|
|
2023
Q1 | – | Sell |
-9,709
| Closed | -$254K | – | 431 |
|
|
2022
Q4 | $254K | Buy |
+9,709
| New | +$129K | ﹤0.01% | 351 |
|
|
2022
Q1 | – | Sell |
-11,959
| Closed | -$80K | – | 443 |
|
|
2021
Q4 | $80K | Hold |
11,959
| – | – | ﹤0.01% | 413 |
|
|
2021
Q3 | $66K | Hold |
11,959
| – | – | ﹤0.01% | 415 |
|
|
2021
Q2 | $78K | Hold |
11,959
| – | – | ﹤0.01% | 416 |
|
|
2021
Q1 | $100K | Hold |
11,959
| – | – | ﹤0.01% | 391 |
|
|
2020
Q4 | $84K | Buy |
+11,959
| New | +$80.8K | ﹤0.01% | 379 |
|
Other funds holding VRNA
Rathbones Group's VRNA Position: Q4 2025 in Review
Rathbones Group sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 2,275 shares — an estimated $243K sold.
Rathbones Group first reported a position in VRNA in Q4 2020 and held it in 16 quarters. The position peaked at $650K in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Rathbones Group reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Rathbones Group sold 2,275 Verona Pharma shares in Q4 2025, an estimated $243K.
- Rathbones Group first reported a position in Verona Pharma in Q4 2020 and held it in 16 quarters.
- Rathbones Group's Verona Pharma position peaked at $650K in Q2 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Rathbones Group's 13F filing for Q4 2025, filed 21 Jan 2026.